Sanofi: Libtayo® (cemiplimab) approved by the European Commission for first-line treatment of patients with advanced non-small cell lung cancer with ≥50% PD-L1 expression

Media coverage

• Title	Sanofi: Libtayo® (cemiplimab) approved by the European Commission for first-line treatment of patients with advanced non-small cell lung cancer with ≥50% PD-L1 expression
  Media name/outlet	Spoke.com
  Country/Territory	United States
  Date	25/06/21
  URL	https://www.spoke.com/press_releases/60d56eaa305335cc220177b0
  Persons	Israel Lowy,

• Title	Sanofi: Libtayo® (cemiplimab) approved by the European Commission for first-line treatment of patients with advanced non-small cell lung cancer with ≥50% PD-L1 expression
  Media name/outlet	Jotup
  Country/Territory	United States
  Date	25/06/21
  URL	https://jotup.co/node/1397975
  Persons	Israel Lowy,

• Title	Sanofi: Libtayo® (cemiplimab) approved by the European Commission for first-line treatment of patients with advanced non-small cell lung cancer with ≥50% PD-L1 expression
  Media name/outlet	BioSpace
  Country/Territory	United States
  Date	25/06/21
  URL	https://www.biospace.com/article/releases/sanofi-libtayo-cemiplimab-approved-by-the-european-commission-for-first-line-treatment-of-patients-with-advanced-non-small-cell-lung-cancer-with-50-percent-pd-l1-expression/?s=95
  Persons	Israel Lowy,

• Title	Sanofi: Libtayo® (cemiplimab) approved by the European Commission for first-line treatment of patients with advanced non-small cell lung cancer with ≥50% PD-L1 expression
  Media name/outlet	CompanyNewsHQ
  Country/Territory	United Kingdom
  Date	25/06/21
  URL	https://www.companynewshq.com/company-news/pharmaceutical-company-news/sanofi-libtayo-cemiplimab-approved-by-the-european-commission-for-first-line-treatment-of-patients-with-advanced-non-small-cell-lung-cancer-with-%e2%89%a550-pd-l1-expression/
  Persons	Israel Lowy,

• Title	Sanofi: Libtayo® (cemiplimab) approved by the European Commission for first-line treatment of patients with advanced non-small cell lung cancer with ≥50% PD-L1 expression
  Media name/outlet	PrimeNewswire (Top News)
  Country/Territory	United States
  Date	25/06/21
  Persons	Israel Lowy,

• Title	Sanofi: Libtayo® (cemiplimab) approved by the European Commission for first-line treatment of patients with advanced non-small cell lung cancer with ≥50% PD-L1 expression
  Media name/outlet	VB Profiles
  Country/Territory	United States
  Date	25/06/21
  URL	https://www.vbprofiles.com/press_releases/60d56fbeb9abe45dbc6661b6
  Persons	Israel Lowy,

• Title	Sanofi: Libtayo® (cemiplimab) approved by the European Commission for first-line treatment of patients with advanced non-small cell lung cancer with ≥50% PD-L1 expression
  Media name/outlet	Sanofi
  Country/Territory	France
  Date	25/06/21
  URL	https://www.sanofi.com/en/media-room/press-releases/2021/2021-06-25-07-00-00-2252992
  Persons	Israel Lowy,